| GTO ID | GTC0510 |
| Trial ID |
NCT04181827
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) |
| Year | 2020 |
| Country | United States |
| Company sponsor | Janssen Research & Development, LLC |
| Other ID(s) | CR108695|2019-001413-16|68284528MMY3002 |